Werewolf Therapeutics (HOWL) shares more than doubled on Friday morning as investors reacted to the company’s definitive agreement to merge with privately held Ambros Therapeutics.
Once the transaction is completed, HOWL shareholders will retain about 6.8% ownership of the joint company, its management revealed in a press release on Aug. 21.